Natera reported second quarter 2026 revenue of $752.8 million, up 37.7% year-over-year, and a narrower-than-expected net loss of $67.0 million. The company processed over 1.04 million total tests, marking its second consecutive million-test quarter, and significantly expanded its oncology footprint with record sequential clinical molecular residual disease (MRD) unit growth and several key regulatory milestones.
Key Highlights
- Total revenue of $752.8 million beat the analyst estimate of $661.26 million, driven by strong volumes and average selling price improvements.
- Oncology test volume surged 57.2% year-over-year to 296,700 units, with clinical MRD units specifically contributing 283,000 tests.
- Management raised fiscal 2026 revenue guidance to a range of $2.85 billion to $2.91 billion, a $100 million increase at the midpoint.